Leukemia Panel-AML Mutation, Bone Marrow

The Leukaemia Panel - AML Mutation test detects specific gene mutations in FLT3, NPM1, and CEBPA in a bone marrow sample.

• To identify specific gene mutations in CN-AML patients for risk stratification • To guide treatment decisions and personalise therapy options • To provide prognostic information for better disease management

The Leukaemia Panel - AML Mutation test is recommended for patients who have been newly diagnosed with cytogenetically normal acute myelogenous leukaemia (CN-AML).

If the Leukaemia Panel - AML Mutation test reveals the presence of specific gene mutations in FLT3, NPM1, or CEBPA, it indicates a higher risk category for patients with cytogenetically normal acute myelogenous leukaemia (CN-AML).

During the test, your doctor will collect a bone marrow sample using a needle. The sample will be sent to the laboratory for analysis.

• Clinical diagnosis, test prescription, referring clinician's contact number, and TRF (Test Request Form) are mandatory. • Follow any instructions provided by your doctor regarding fasting or medication adjustments. • Inform your doctor if you have any specific requirements.

• Genetic testing for other gene mutations associated with AML • Cytogenetic analysis to study chromosomal abnormalities • Complete blood count (CBC) to assess overall blood cell counts • Bone marrow biopsy for detailed examination of the bone marrow

FLT3/NPM1/CEBPA mutation analysis or Acute Myeloid Leukemia Mutation Panel

Acute Myelogenous Leukemia is a type of cancer that starts in the bone marrow, where blood cells are produced. It affects the myeloid cells, which would normally develop into red blood cells, white blood cells, and platelets. AML can disrupt normal blood cell production and lead to various symptoms and complications.